Related references
Note: Only part of the references are listed.Nirmatrelvir/ritonavir use: Managing clinically significant drug-drug interactions with transplant immunosuppressants
Nicholas W. Lange et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2022)
Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis, therapeutics and vaccines
Queenie Fernandes et al.
ANNALS OF MEDICINE (2022)
SARS-CoV-2 Omicron variant is highly sensitive to molnupiravir, nirmatrelvir, and the combination
Pengfei Li et al.
CELL RESEARCH (2022)
Disposition of Nirmatrelvir, an Orally Bioavailable Inhibitor of SARS-CoV-2 3C-Like Protease, across Animals and HumansS
Heather Eng et al.
DRUG METABOLISM AND DISPOSITION (2022)
Characterization of the non-covalent interaction between the PF-07321332 inhibitor and the SARS-CoV-2 main protease
Marina Macchiagodena et al.
JOURNAL OF MOLECULAR GRAPHICS & MODELLING (2022)
Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19
Jennifer Hammond et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
Crystal structure of SARS-CoV-2 main protease in complex with protease inhibitor PF-07321332
Yao Zhao et al.
PROTEIN & CELL (2022)
Validation and invalidation of SARS-CoV-2 main protease inhibitors using the Flip-GFP and Protease-Glo luciferase assays
Chunlong Ma et al.
ACTA PHARMACEUTICA SINICA B (2022)
Oral Nirmatrelvir/Ritonavir Therapy for COVID-19: The Dawn in the Dark?
Yuan-Pin Hung et al.
ANTIBIOTICS-BASEL (2022)
Main protease mutants of SARS-CoV-2 variants remain susceptible to nirmatrelvir
Sven Ullrich et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2022)
Covalent Reversible Inhibitors of Cysteine Proteases Containing the Nitrile Warhead: Recent Advancement in the Field of Viral and Parasitic Diseases
Simone Brogi et al.
MOLECULES (2022)
SARS-CoV-2 Mpro inhibitors and activity-based probes for patient-sample imaging
Wioletta Rut et al.
NATURE CHEMICAL BIOLOGY (2021)
Public health actions to control new SARS-CoV-2 variants Comment
Nathan D. Grubaugh et al.
CELL (2021)
Caution required with use of ritonavir-boosted PF-07321332 in COVID-19 management
Joseph Heskin et al.
LANCET (2021)
HEAVILY MUTATED OMICRON VARIANT PUTS SCIENTISTS ON ALERT
Ewen Callaway
NATURE (2021)
An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-19
Dafydd R. Owen et al.
SCIENCE (2021)
Considerations for the discovery and development of 3-chymotrypsin-like cysteine protease inhibitors targeting SARS-CoV-2 infection
Koen Vandyck et al.
CURRENT OPINION IN VIROLOGY (2021)
The need for a multi-level drug targeting strategy to curb the COVID-19 pandemic
George J. Kontoghiorghes et al.
FRONTIERS IN BIOSCIENCE-LANDMARK (2021)
Peptidomimetic nitrile warheads as SARS-CoV-2 3CL protease inhibitors
Bing Bai et al.
RSC MEDICINAL CHEMISTRY (2021)
Pharmacokinetic enhancers (cobicistat/ritonavir) and the potential for drug-drug interactions
Paul Hollywood et al.
IRISH JOURNAL OF MEDICAL SCIENCE (2020)
A new coronavirus associated with human respiratory disease in China
Fan Wu et al.
NATURE (2020)
Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors
Zhenming Jin et al.
NATURE (2020)
Boceprevir, GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease
Chunlong Ma et al.
CELL RESEARCH (2020)
The SARS-CoV-2 main protease as drug target
Sven Ullrich et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2020)
Both Boceprevir and GC376 efficaciously inhibit SARS-CoV-2 by targeting its main protease
Lifeng Fu et al.
NATURE COMMUNICATIONS (2020)
Characterising covalent warhead reactivity
James S. Martin et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2019)
Structure-based design and in vivo anti-arthritic activity evaluation of a potent dipeptidyl cyclopropyl nitrile inhibitor of cathepsin C
Brice Korkmaz et al.
BIOCHEMICAL PHARMACOLOGY (2019)
Emerging and Re-Emerging Warheads for Targeted Covalent Inhibitors: Applications in Medicinal Chemistry and Chemical Biology
Matthias Gehringer et al.
JOURNAL OF MEDICINAL CHEMISTRY (2019)
A comparative study of warheads for design of cysteine protease inhibitors
Daniel G. Silva et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2017)
An Overview of Severe Acute Respiratory Syndrome-Coronavirus (SARS-CoV) 3CL Protease Inhibitors: Peptidomimetics and Small Molecule Chemotherapy
Thanigaimalai Pillaiyar et al.
JOURNAL OF MEDICINAL CHEMISTRY (2016)
Cyanohydrin as an Anchoring Group for Potent and Selective Inhibitors of Enterovirus 71 3C Protease
Yangyang Zhai et al.
JOURNAL OF MEDICINAL CHEMISTRY (2015)
Reversible Cysteine Protease Inhibitors Show Promise for a Chagas Disease Cure
Momar Ndao et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2014)
Design, synthesis and crystallographic analysis of nitrile-based broad-spectrum peptidomimetic inhibitors for coronavirus 3C-like proteases
Chi-Pang Chuck et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2013)
3C Protease of Enterovirus 68: Structure-Based Design of Michael Acceptor Inhibitors and Their Broad-Spectrum Antiviral Effects against Picornaviruses
Jinzhi Tan et al.
JOURNAL OF VIROLOGY (2013)
Discovery of boceprevir, a direct-acting NS3/4A protease inhibitor for treatment of chronic hepatitis C infections
Srikanth Venkatraman
TRENDS IN PHARMACOLOGICAL SCIENCES (2012)
Mutation of Glu-166 Blocks the Substrate-Induced Dimerization of SARS Coronavirus Main Protease
Shu-Chun Cheng et al.
BIOPHYSICAL JOURNAL (2010)
Design and synthesis of dipeptidyl glutaminyl fluoromethyl ketones as potent severe acute respiratory syndrome coronovirus (SARS-CoV) inhibitors
HZ Zhang et al.
JOURNAL OF MEDICINAL CHEMISTRY (2006)
The substrate specificity of SARS coronavirus 3C-like proteinase
KQ Fan et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2005)
Share Paper
